₹0.52
(Market cap
₹86 Cr
Recently Viewed
Clear AllMarket cap
₹86 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
116.7
P/B Ratio
3.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹1 Cr
ROE
3.2 %
ROCE
3 %
Industry P/E
45.59
EV/EBITDA
87.3
Debt to Equity
0
Book Value
₹18.7
EPS
₹1.2
Face value
10
Shares outstanding
14,353,000
CFO
₹-3.34 Cr
EBITDA
₹-6.33 Cr
Net Profit
₹-8.33 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bacil Pharma
| 68.0 | 19.8 | 47.1 | 37.1 | 127.1 | 72.2 | 26.4 |
|
BSE Healthcare
| -1.9 | -1.8 | -2.4 | 7.7 | 24.3 | 13.4 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bacil Pharma
| -33.1 | 736.0 | -31.7 | 31.5 | 51.0 | 148.4 | -13.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bacil Pharma
|
59.9 | 86.0 | 0.0 | 0.7 | -- | 2.8 | 116.7 | 3.2 |
| 2,362.2 | 19,341.2 | 1,215.1 | 284.8 | 28.7 | 21.1 | 67.4 | 12.7 | |
| 724.2 | 14,204.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 22.6 | 2.6 | |
| 632.0 | 15,681.8 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.7 | 3.5 | |
| 890.8 | 14,176.0 | 7,918.4 | 429.9 | 10.7 | 7.2 | 32.8 | 2.1 | |
| 1,104.2 | 19,771.9 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.7 | 2.2 | |
| 1,438.9 | 16,451.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 818.4 | 2.8 | |
| 146.0 | 19,420.3 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 404.7 | 16,302.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 46.3 | 3.4 | |
| 1,343.8 | 21,839.8 | 3,151.0 | -10.0 | 8.4 | 2.5 | 992.7 | 4.7 |
No Review & Analysis are available.
Bacil Pharma Limited manufactures and sells pharmaceuticals, medicinal chemicals, and botanical products. The company was incorporated in 1987 and is based in Mumbai, India.
Incorporated
1987
Chairman
--
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClarification On Price Movement
24-Feb-2026Clarification sought from Bacil Pharma Ltd
24-Feb-2026
The share price of Bacil Pharma Ltd is ₹59.89 (BSE) as of 10-Apr-2026 IST. Bacil Pharma Ltd has given a return of 127.15% in the last 3 years.
The P/E ratio of Bacil Pharma Ltd is 116.65 times as on 10-Apr-2026, a 156 premium to its peers’ median range of 45.59 times.
The P/B ratio of Bacil Pharma Ltd is 3.21 times as on 10-Apr-2026, a 1 premium to its peers’ median range of 3.19 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
140.14
|
2.28
|
|
2024
|
0.00
|
14.96
|
|
2023
|
0.00
|
6.98
|
|
2022
|
0.00
|
5.75
|
|
2021
|
0.00
|
2.44
|
The 52-week high and low of Bacil Pharma Ltd are Rs 61.80 and Rs 26.69 as of 10-Apr-2026.
Bacil Pharma Ltd has a market capitalisation of ₹ 86 Cr as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bacil Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.